A DNA-Peptide Fusion as a Vaccine Candidate against Breast and Ovarian Cancer Metastasis: Consequent Benefit in Certain Lung Cancers

Abstract

Cancer mortality data were obtained from the WHO Mortality Database. Lung cancer, with about 85% being non-small cell lung cancer is one of the most common malignant tumors, considered the leading cause of cancer-related death in both men and women (associated with breast and ovarian cancer in metastasis). From published data, we designed a preventive vaccine in Silico aimed to protect against breast and ovarian cancer involved in metastasis for lung cancer. The largest increases are expected for melanoma; cancers of the prostate, kidney, liver, and urinary bladder in males; and the lung, breast, uterus, ovarian, and thyroid in females. Among all women, lung cancer mortality rates have surpassed those for breast cancer around the world. This reflects the decline of breast cancer mortality due to screening access and effective treatment alongside entrance of certain countries lifestyle and behavior in which smoking has become more prevalent in women. One aim of this research paper is to provide a better understanding for the potential dormant repositories of outbreaks and potential metastasis of breast and ovarian cancer and its consequents in lung cancer. In this study, we present to the cDNA-peptide fusion a more stable anti-tumoral against breast and ovarian cancer. As a cDNA target, we used primers from Her2 gene fusion with peptides from Her2 and human PARP-1 proteins. Our analysis identified 16 cloning DNA (cDNA) with theorical fusion stability (FS) value among 49.30-62.41 range and theorical Exosome Affinity (EA) (cDNA-peptide and exosome) among 62.60-77.10 range. We proposed a cDNA-peptide with theorical fusion value stability FS=50.36 Cruz and exosome affinity EA=68.02 Ro. We have named the cDNA-peptide selection as: LCR_2020_B008-55. In addition, in Silico, this cDNA-peptide also manifests partial inhibiting activity on the methylated promoter genes in lung tumors, therefore, this chimera cDNA-peptide may achieve a higher representative antitumoral activity against lung cancer disease. According to the anti-tumoral monitoring after and before vaccination using the candidate LCR_2020_B008-55, we proposed exosomes as biomarkers of lung carcinogenesis after and before vaccination. Due to the cDNA-peptides, in Silico, manifesting high affinity with exosomes, where our proposed vaccine may reach high representative activity against breast, ovarian and lung cancer in a metastasis stage, we identified this chimera with a triple antitumoral action.